Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
86,510 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| May 14, 2026 | HealthPartners | Peanut (arachis hypoqaea) allergen powder-dnfp (Palforzia)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-227048 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | OxygenPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046423 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Orthotics, braces, and shoes – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-184945 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Orthotics, braces, and shoes – Iowa, North Dakota, South Dakota, and WisconsinPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046070 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology** - rituximab (Rituxan, Ruxience, Truxima, Rituxan Hycela, and Riabni) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-228488 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology** - omidubicel-onlv (Omisirge)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-267798 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology testing: cancer screening and surveillancePayerPolicy · HEALTHPARTNERS-CC-ENTRY-232429 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology drug coverage – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-202906 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology drug coveragePayerPolicy · HEALTHPARTNERS-CC-ENTRY-190828 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - trabectedin (Yondelis) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-234241 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - talimogene laherparepvec (Imlygic) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-234242 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology – blastic plasmacytoid dendritic cell neoplasm (BPDCN) drug therapy – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-227133 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - blastic plasmacytoid dendritic cell neoplasm (BPDCN) drug therapyPayerPolicy · HEALTHPARTNERS-CC-ENTRY-210226 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - tafasitamab-cxix (Monjuvi) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-233977 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - polatuzumab Vedotin-piiq (Polivy) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-233978 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-233979 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - necitumumab (Portrazza)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-183254 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - moxetumomab pasudotox-tdfk (Lumoxiti)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-207225 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - luspatercept-aamt (Reblozyl) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-227132 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - luspatercept-aamt (Reblozyl) and imetelstat (Rytelo)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-226974 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - long-acting G-CSF – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-228289 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - long-acting G-CSFPayerPolicy · HEALTHPARTNERS-CC-ENTRY-203757 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - lifileucel (Amtagvi)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-273417 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - isatuximab-irfc (Sarclisa) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-231645 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - ipilimumab (Yervoy)PayerPolicy · HEALTHPARTNERS-CC-AENTRY-046023 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - inotuzumab ozogamicin (Besponsa) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-202917 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - gene therapy for bladder cancer (Adstiladrin)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-266662 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - gemcitabine intravesical system (Inlexzo)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-287010 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - enfortumab vedotin-ejfv (Padcev) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-226865 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - datopotamab deruxtecan-dlnk (Datroway)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-284657 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - daratumumab and daratumumab hyaluronidase-fihj (Darzalex and Darzalex Faspro)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-267748 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - copanlisib (Aliqopa) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-221634 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - chimeric antigen receptor/genetically engineered T-cell receptor (CAR-T) therapyPayerPolicy · HEALTHPARTNERS-CC-ENTRY-198232 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - cemiplimab-rwlc (Libtayo) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-221633 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - blinatumomab (Blincyto)PayerPolicy · HEALTHPARTNERS-CC-AENTRY-045816 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - bevacizumab (Avastin, Mvasi, Zirabev, Alymsys, Vegzelma, Jobevne)PayerPolicy · HEALTHPARTNERS-CC-AENTRY-045654 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - belantamab (Blenrep) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-233951 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - atezolizumab (Tecentriq) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-233952 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oncology - ado-trastuzumab emtansine (Kadcyla), pertuzumab (Perjeta), trastuzumab (Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera), and trastuzumab and hyaluronidase-oysk (Herceptin Hylecta) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-227137 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Olipudase alfa-rpcp (Xenpozyme)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-257855 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Ocular complement inhibitorsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-260879 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Ocular anti-VEGF medicationsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-223233 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Ocrelizumab (Ocrevus) and ocrelizumab hya-ocsq (Ocrevus Zunovo) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-194059 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Ocrelizumab (Ocrevus) and ocrelizumab hya-ocsq (Ocrevus Zunovo)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-193159 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Oral and enteral nutrition - Iowa, North Dakota, South Dakota, and WisconsinPayerPolicy · HEALTHPARTNERS-CC-ENTRY-183853 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Nutritional support - Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046323 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Nusinersen (Spinraza)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-191273 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Neuromuscular electrical stimulation (NMES) and functional electrical stimulation (FES)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-206035 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Neonatal Fc receptor antagonists (Vyvgart, Vyvgart Hytrulo, Rystiggo, Imaavy)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-252184 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Natalizumab (Tysabri, Tyruko) - Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-187829 | Criteria changed |
|---|